Open Actively Recruiting

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL


Brief Summary

This study evaluates nirogacestat in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). Half of the participants will receive nirogacestat while the other half will receive placebo. Allogeneic hematopoietic stem cell transplantation is an accepted therapy for children with high-risk acute ALL. B-ALL or B Cell Acute Lymphoblastic leukemia is a disease originating in the bone marrow and cause for the depletion of B-cells that are responsible for immunity against infection in the human body. Published literature indicates that the inclusion of total body irradiation (TBI) in the HCT conditioning regimen is associated with significant late effects, especially in children because of concerns regarding long-term growth and cognitive function. Total Body Irradiation is radiation therapy given to your entire body with the intention of damaging cancer cells and making it harder for them to reproduce. In addition, TBI is given to decrease response of the immune system to foreign cells from a donor. Hematopoietic cell transplantation is the intravenous infusion of hematopoietic stem cells designed to re-establish marrow and immune function in patients with disorders. Detection of MRD (minimal residual disease) prior to HCT of children with ALL is predictive of relapse and poor survival. MRD is defined as the small number of Leukaemic cells, if any, that remain in the patient during treatment or after the treatment when the patient has achieved remission. Event-free and overall survival of pediatric B-ALL allogeneic HCT recipients is >50%, but could be >90% for patients who are next-generation sequence minimal residual disease negative prior to HCT. The current standard treatment for B-ALL, uses TBI-based conditioning that causes high rates of late effects compared to sibling controls, contributing to a 4 to 9 fold higher rate of early mortality compared to the general population. HCT survivors experience endocrinopathies, organ dysfunction, cardiac and metabolic disorders and secondary malignancies. Young patients (<3 years of age) may be at greatest risk of TBI related late effects, but risk of chronic health conditions are significant regardless of age in HCT survivors. A Phase II pilot trial will estimate survival after a non-TBI (total body irradiation) or non-radiative based approach followed by a conditioning regimen in patients between the ages of 1 to 25 years diagnosed with B-acute lymphoblastic leukemia (ALL). These patients are pre-allogeneic hematopoietic cell transplantation (HCT) patients and have minimal residual disease (MRD) negative as defined by next-generation-sequence (NGS). Minimal residual disease analysis through Next Generation Sequence is completed through peripheral blood and bone marrow sampling. Additionally, the study will include peripheral blood collection, echocardiogram, pulmonary function tests and lumbar puncture.

Myeloablative non-TBI conditioning with busulfan, fludarabine, and thiotepa followed -matched related, unrelated, and umbilical cord blood transplants. Study duration is 5 years or until relapse of leukemia. The accrual objective study-wide is 70 subjects for the treatment arm and 95 subjects for the observational arm. At our site, our goal is to enroll 5 patients in the study.

Primary Purpose
Study Type
Phase II


Healthy Volunteers
Minimum Age
1 Year
Maximum Age
25 Years

Pediatric patients diagnosed with B-acute lymphoblastic leukemia (ALL). For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Inclusion Criteria for the Observational Arm:

Any patient with ALL who undergoes Myeloablative HCT including any of the following:

  • Patients who are pre-HCT NGS-MRD positive.
  • Patients <1 year old who are pre-HCT NGS-MRD negative.
  • Patients who are pre-HCT NGS-MRD negative (CR1/CR2) who received inotuzumab ozogamicin therapy before proceeding to HCT.
  • Patients who are pre-HCT NGS-MRD negative and will be receiving haploidentical HCT.
  • Patients who are pre-HCT NGS-MRD negative in CR2 with history of CNS relapse.
  • Patients who have received blinatumomab, but are >CR2 prior to HCT.
  • Patients who have received CART-T cellular therapy, but are >CR2 prior to HCT.
  • Patients with pre-HCT NGS-MRD negative in ≥ CR3.
  • Any T-ALL and MPAL patients undergoing first allogeneic HCT
  • Any patient who is pre-HCT NGS-MRD negative and eligible for participation in the treatment arm but family does not consent for treatment arm or treating physician believe it is in the patient best interest not to enroll on the treatment arm

Inclusion Criteria for the Treatment Arm:

  • Pre-HCT NGS-MRD negative
  • Age ≥ 1 year and ≤ 25 years
  • Disease status: B-ALL in first (CR1) or second remission (CR2)
  • No prior allogeneic hematopoietic stem cell transplant.
  • Patients in CR1 or CR2 after blinatumomab treatment.
  • Patients in CR1 or CR2 after CAR-T cellular therapy.
  • Karnofsky Index or Lansky Play-Performance Scale ≥ 60 % on pre-transplant evaluation. Karnofsky scores must be used for patients > 16 years of age and Lansky scores for patients < 16 years of age.
  • Able to give informed consent if > 18 years, or with a legal guardian capable of giving informed consent if < 18 years.
  • Adequate organ function (within 4 weeks of initiation of preparative regimen), defined as:
  • Pulmonary: FEV1, FVC, and corrected DLCO must all be ≥ 50% of predicted by pulmonary function tests (PFTs). For children who are unable to perform for PFTs due to age, the criteria are: no evidence of dyspnea at rest and no need for supplemental oxygen.
  • Renal: Creatinine clearance or radioisotope GFR ≥ 60 mL/min/1.73 m2 or a serum creatinine based on age/gender.
  • Cardiac: Shortening fraction of ≥ 27% by echocardiogram or radionuclide scan (MUGA) or ejection fraction of ≥ 50% by echocardiogram or radionuclide scan (MUGA), choice of test according to local standard of care.
  • Hepatic: SGOT (AST) or SGPT (ALT) < 5 x upper limit of normal (ULN) for age. Conjugated bilirubin < 2.5 mg/dL, unless attributable to Gilbert's Syndrome.

Exclusion Criteria:

  • CR2: exclude patients with history of CNS relapse (i.e. in CR2 with history of CNS isolated or combined relapse; CNS 2 will also be considered as CNS 3 for this purpose) from the treatment arm of study (can be enrolled on the observational arm).
  • Patients who have received inotuzumab treatment prior to allogeneic HCT are NOT eligible for the study treatment arm. Inotuzumab treatment may increase the risk of VOD/SOS for any allogeneic HCT recipient, but could potentiate the risk for with busulfan-based myeloablation (study-directed non-TBI conditioning). All inotuzumab-treated patients are eligible for the observational arm (HCT center standard of care).
  • Patients receiving non-myeloablative conditioning are not allowed on the observational arm (reduced toxicity conditioning with Flu/Mel/Thio is allowed on the observational arm).
  • Pregnant or lactating females are ineligible as many of the medications used in this protocol could be harmful to unborn children and infants.
  • Patients with HIV or uncontrolled fungal, bacterial or viral infections are excluded. Patients with history of fungal disease during induction therapy may proceed if they have a significant response to antifungal therapy with no evidence or minimal evidence of non-progressive disease remaining by CT evaluation.
  • Patients with active CNS leukemia or any other active site of extramedullary disease at the time of enrollment are not permitted.
  • T-ALL and MPAL patients are only allowed on the observational arm.
  • Patients with genetic disorders (generally marrow failure syndromes) prone to secondary AML/ALL with known poor outcome are not eligible (Fanconi Anemia, Kostmann Syndrome, Dyskeratosis Congenita, etc).

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
Andres Vargas Gonzalez
  • UCLA Westwood
For Providers
For detailed technical eligibility, visit